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Abstract 
Background: Asthma affects up to nearly 40% of patients with allergic rhinitis (AR). Poor control of AR symptoms is 
associated with poor asthma control. The goal of this study was to evaluate the effect of AR treatment with MP‑AzeFlu 
on symptoms of AR as well as symptoms of asthma.
Methods: This prospective study used a visual analog scale (VAS) to assess symptoms of AR and asthma before 
and after treatment with MP‑AzeFlu  (Dymista®; azelastine hydrochloride plus fluticasone propionate; 1 spray in each 
nostril twice daily for 2 weeks). Participants suffered from moderate‑to‑severe AR according to Allergic Rhinitis and its 
Impact on Asthma criteria, with acute AR symptoms (AR‑VAS scores ≥ 50 mm) on inclusion day. In addition to symp‑
tom assessment, patients recorded the impact of AR symptoms on quality‑of‑life measures before, during, and at the 
conclusion of the treatment period (approximately 14 days). Patients self‑reported change in frequency of their usage 
of asthma reliever medication on the last day of treatment.
Results: Of 1103 study participants, 267 (24.2%) had comorbid asthma. These participants reported using a mean 
of 5.1 puffs of asthma reliever medication in the week before treatment with MP‑AzeFlu. A total of 81.8% of patients 
with comorbid asthma responded to AR therapy (AR‑VAS < 50 mm on at least 1 study day). Among patients with AR 
and comorbid asthma, MP‑AzeFlu was associated with improved VAS scores across all study parameters, including AR 
symptom severity, asthma symptom severity, sleep quality, daily work or school activities, daily social activities, and 
daily outdoor activities. Asthma symptom severity decreased from a mean of 48.9 mm to 24.1 mm on the VAS. Self‑
reported frequency of asthma reliever medication use was reduced for 57.6% of participants (n = 139/241).
Conclusion: MP‑AzeFlu used to relieve AR symptoms was associated with reduced asthma symptom VAS scores and 
frequency of asthma reliever medication usage. Changes in overall symptoms of AR and asthma were correlated.
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Background
Globally, allergic rhinitis (AR) is a common, systemic 
allergic disease, with a prevalence of up to 25% in chil-
dren and 40% in adults [1]. Among patients with AR, 
other allergic disorders are frequently comorbid [2]. 
Between 15% and nearly 40% of patients with AR have 
comorbid asthma, whereas asthma prevalence in the gen-
eral population is approximately 7% [1, 3].
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Among patients with AR who visited a general practi-
tioner, the majority—more than 90%—have moderate-
to-severe intermittent or persistent disease [4]. Many 
patients with moderate-to-severe AR have poorly con-
trolled asthma [3], which may be attributable in part 
to lower airway inflammation [3]. In a survey of 520 
patients with asthma, asthma was significantly less likely 
to be controlled in patients with moderate-to-severe, 
persistent AR compared with those with intermittent 
AR (65.7% vs 20.4%; P < 0.01) [4]. Furthermore, patients 
with AR and asthma comorbidity have higher healthcare 
resource utilization, including clinic visits, hospitaliza-
tions, and pharmacy costs over a 12-month time period 
[5]. Direct costs of AR are significantly higher for patients 
with mild-persistent asthma (€719) or moderate-persis-
tent asthma (€799) than for the general population with 
AR (€554) [6].
Treatment of AR may concurrently improve AR and 
asthma symptoms in patients with comorbid disease 
[7–9]. In a past study, failure to manage AR symptoms 
was associated with increased use of asthma medications 
[7]. When patients with moderate-to-severe AR forgot to 
use their AR medication, more than half of those patients 
reported having to increase use of asthma reliever medi-
cations and 19.5% reported a need to increase asthma 
controller medication use [7]. Furthermore, in observa-
tional studies, AR treatment has been shown to improve 
upper and lower airway outcomes and decrease the 
risk for asthma-related hospitalization and emergency 
department visits by half [8, 9].
Treatments for AR include oral  H1 antihistamines, 
intranasal corticosteroids (INCS), or intranasal antihista-
mines (INAH) [1]. Despite the wide variety of medication 
options available, many patients are dissatisfied with their 
AR treatment, resulting in poor adherence [10]. There-
fore, combination therapies may improve satisfaction by 
reducing medication burden in patients with moderate-
to-severe, persistent AR symptoms. In the Allergic Rhi-
nitis and its Impact on Asthma (ARIA) 2016 guideline 
update, combination treatment with INCS and INAH is 
recommended for patients with AR [1].
Azelastine hydrochloride has been formulated with flu-
ticasone propionate in a single intranasal spray (MP-Aze-
Flu;  Dymista®) for the treatment of AR [11]. Compared 
with fluticasone propionate or azelastine hydrochlo-
ride alone, MP-AzeFlu resulted in significantly greater 
improvements in AR symptoms, including nasal conges-
tion, one of the most bothersome and prevalent symp-
toms of AR, [12–14] nasal cell inflammation [15], loss 
of smell [16], and nasal hyperreactivity [17]. Relative to 
individual dosing of both an INAH and INCS, MP-Aze-
Flu was also associated with lower pharmacy costs and 
total costs in a prior database analysis [18].
The purpose of this analysis of a real-world study was 
to evaluate the effect of MP-AzeFlu on asthma symp-
toms and frequency of use of asthma reliever medica-
tion in patients with comorbid AR and asthma.
Methods
Study design
This was a multinational, multicenter, prospective, non-
interventional, real-life study conducted in 6 European 
countries: Austria, Germany, Czech Republic, Hungary, 
Netherlands, and Ireland. The study ran from Febru-
ary 21, 2018, to April 30, 2019. Ethics approval was 
obtained according to guidelines and procedures of 
the respective countries. Physicians who were usually 
involved in the management of AR and routinely used 
a visual analog scale (VAS) for symptom assessment 
in patients with AR were invited to participate in the 
study. Participating physicians included general practi-
tioners, allergists, otorhinolaryngologists, pulmonolo-
gists, dermatologists, and pediatricians.
The study consisted of an inclusion visit (day 0) and 
a control visit after about 14  days, allowing for some 
flexibility depending on usual clinical practice. Patients 
received patient cards at the inclusion visit to record 
AR symptoms, asthma symptoms, and other outcomes 
using a VAS. Physicians collected patient cards at the 
control visit, on or around day 14 or by mail.
Participants
Physicians enrolled patients with moderate-to-severe 
seasonal or perennial AR according to ARIA criteria, 
for whom MP-AzeFlu was prescribed for the first time. 
Decisions to include patients in the study were made by 
the physicians independently from and after the deci-
sion to prescribe MP-AzeFlu to the patient.
Inclusion criteria included first-time prescription 
of MP-AzeFlu according to the summary of product 
characteristics, age 12  years or older, moderate-to-
severe AR according to ARIA criteria [19], acute symp-
toms of AR on the day of inclusion (AR symptoms 
VAS ≥ 50 mm), written informed consent by the patient 
and (if applicable) caregiver for patients younger than 
18 years, ability to understand the instructions for use 
of MP-AzeFlu according to the summary of product 
characteristics and patient leaflet, and ability to return 
the completed patient card.
Exclusion criteria included known allergic reactions 
to MP-AzeFlu or any of its ingredients, pregnancy or 
planned pregnancy, breastfeeding, inability to provide 
informed consent, or missing consent.
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Study treatment
All patients received MP-AzeFlu. MP-AzeFlu was 
dosed as outlined in the country-specific summary of 
product characteristics: 1 spray in each nostril twice 
daily (total daily dose: 548 µg azelastine hydrochloride 
and 200 µg fluticasone propionate) for 2 weeks. Physi-
cians ensured that the patient properly understood the 
instructions for use, as specified in the summary of 
product characteristics and patient information leaflet.
Study measures/outcomes
On day 0, the physician documented patient demo-
graphics, AR symptoms, and previous treatments of 
AR in an electronic case report form. Patient recol-
lections of their AR symptoms over the past 24 h were 
measured using a printed single-line VAS (AR-VAS) 
in the patient card, ranging from “not at all bother-
some” (0  mm) to “extremely bothersome” (100  mm). 
AR symptom severity VAS scores and, for patients who 
suffered from asthma, asthma symptom severity VAS 
scores, were documented on the patient’s card on days 
0, 1, 3, 7, and ~ 14. Response was defined as an AR-VAS 
rating < 50  mm (indicating controlled AR) [20] at least 
once during the study.
On days 0, 7, and ~ 14, patients assessed their sleep 
quality and troublesomeness in daily activities over 
the past 7  days, from “not at all troubled” (0  mm) to 
“extremely troubled” (100 mm). For patients who suffered 
from asthma, information on frequency of use of asthma 
reliever medication was collected at baseline. At the end 
of the documentation period (day ~ 14), the self-reported 
change in the frequency of use of asthma reliever medi-
cation was recorded as significantly reduced, reduced, 
equal, increased, or significantly increased. All suspected 
adverse drug reactions were documented in the case 
reports.
Statistical methods
Subpopulation analyses were performed for patients with 
AR but no asthma and for patients with AR and asthma 
comorbidity. The responder rate was calculated for the 
study population. Statistical analyses were performed 
using the statistical software package SAS (SAS Institute 
Inc.; Cary, NC, USA) version 9.4 or higher.
Results
Study population
Of 1154 enrolled patients, 51 were excluded from data 
analysis because their data had not been confirmed 
by the investigator. The 1103 remaining patients were 
included in the safety analysis. A total of 267 patients 
listed asthma as a comorbidity. Patient demographics and 
baseline characteristics are detailed in Table 1.
AR symptom response
In the total study population, all 1103 patients were 
included in the responder rate analysis. Among the 
915 patients reporting previous AR treatment, the 
most commonly used symptomatic AR treatments 
were oral, nonsedating  H1-antihistamine (n = 506; 
45.9%), INCS (n = 471; 42.7%), intranasal decongestant 
(n = 191; 17.3%), INAH (n = 177; 16.0%), oral, first-gen-
eration  H1-antihistamine (n = 162; 14.7%), and ocular 
 H1-antihistamine (n = 133; 12.1%).
Treatment response was defined as an AR-VAS 
score < 50  mm, the cutoff that differentiates controlled 
AR from uncontrolled AR [20], on any 1 day. A total of 
944 patients [86.6%; 95% confidence interval (CI), 84.5–
88.5%) met the response criteria, including 728 patients 
without asthma (88.1%; 95% CI 85.8–90.2%) and 216 
patients with asthma (81.8%; 95% CI 76.7–86.0%). Over 
the course of treatment, the mean [standard deviation 
(SD)] VAS decreased by 46.2 (23.3)  mm from baseline 
to the last day (Fig.  1). The mean (SD) change in AR-
VAS over the study period for patients with AR without 
asthma was − 46.4 (22.9)  mm; for AR with comorbid 
asthma, it was − 45.3 (25.2)  mm. For patients with and 
without comorbid asthma, the AR-VAS change from 
baseline was significant at every time point (P < 0.0001). 
Furthermore, no significant differences were observed 
between patients with and without asthma in AR-VAS 
change at any time point.
Asthma symptom response
Among the subpopulation of patients with asthma, 
patients rated their asthma symptoms on a VAS. The 
mean (SD) asthma-VAS score decreased from 48.9 
(29.3) mm at baseline to 24.1 (21.9) mm on the last day, 
resulting in a mean change of − 25.7 (26.0) mm (Fig. 2). 
Changes from baseline for AR symptoms and asthma 
symptoms were moderately correlated (Pearson correla-
tion coefficient, 0.47; P < 0.0001).
Participants with asthma reported using reliever 
medication a mean of 5.1 times during the week before 
treatment. Self-reported data regarding frequency of 
asthma reliever medication use during the study period 
were available for 241 patients (85.0%). A total of 139 
patients (57.6%) reported that the frequency of asthma 
reliever use was either considerably reduced or reduced. 
In addition, 93 patients (38.6%) reported no change, and 
9 patients (3.7%) reported an increased frequency of 
asthma reliever medication use.
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Table 1 Patient Baseline Demographics
AR indicates allergic rhinitis, SD standard deviation, VAS visual analog scale
a Percentages may not equal 100 due to rounding
Baseline characteristics Total study population (N = 1103) AR with no asthma (n = 836) AR 
with asthma 
(n = 267)
 Gender, n (%)
  Male 474 (43.0) 355 (42.5) 119 (44.6)
  Female 624 (56.6) 478 (57.2) 146 (54.7)
  Missing 5 (0.5) 3 (0.4) 2 (0.8)
 Age, n (%)
  12–17 years 82 (7.4) 67 (8.0) 15 (5.6)
  18–65 years 937 (85.0) 711 (85.0) 226 (84.6)
  > 65 years 84 (7.6) 58 (6.9) 26 (9.7)
 Allergic sensitization (number of allergens), n (%)
  1 178 (16.1) 152 (18.2) 26 (9.7)
  2–5 570 (51.7) 428 (51.2) 142 (53.2)
  > 5 176 (16.0) 96 (11.5) 80 (30.0)
  Unknown 179 (16.2) 160 (19.1) 19 (7.1)
 Type of AR, n (%)
  Perennial only 120 (10.9) 102 (12.2) 18 (6.7)
  Seasonal only 435 (39.4) 354 (42.3) 81 (30.3)
  Perennial and seasonal 444 (40.3) 285 (34.1) 159 (59.6)
  Missing 104 (9.4) 95 (11.4) 9 (3.4)
 Allergic comorbidities, n (%)
  Asthma 267 (24.2) 0 (0) 267 (100)
  Dermatitis/eczema 127 (11.5) 90 (10.8) 37 (13.9)
  Food allergy/allergies 109 (9.9) 81 (9.7) 28 (10.5)
  Severe allergic reactions 30 (2.7) 18 (2.2) 12 (4.5)
  None 593 (53.8) 593 (70.9) 0
  Missing 89 (8.1) 89 (10.6) 0
 Baseline AR‑VAS scores, mean (SD)
  AR‑VAS scores 73.2 (13.4) 72.8 (13.4) 74.1 (13.5)
 Previous symptomatic AR treatments since last year, n (%)
  Oral, nonsedating  H1‑antihistamine 506 (45.9)
  Intranasal corticosteroid 471 (42.7)
  Intranasal decongestant 191 (17.3)
  Intranasal  H1‑antihistamine 177 (16.0)
  Oral, first‑generation  H1‑antihistamine 162 (14.7)
  Ocular  H1‑antihistamine 133 (12.1)
  Oral or nebulized corticosteroid 99 (9.0)
  Intranasal mast cell stabilizer 62 (5.6)
  Oral leukotriene antagonist 50 (4.5)
  Ocular mast cell stabilizer 42 (3.8)
  Oral decongestant 26 (2.4)
  Other 54 (4.9)
  Unknown 24 (2.2)
  None 164 (14.9)
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Quality‑of‑life measurements
Troublesomeness of sleep
Changes in quality-of-life measurements are reported 
in Fig.  3 through Fig.  6. In the whole study population, 
mean (SD) troublesomeness with sleep quality VAS score 
significantly decreased by − 33.7 (28.1) mm from day 0 to 
the last day (P < 0.0001). Similarly, among the subpopu-
lation of AR with asthma, mean (SD) troublesomeness 
with sleep quality VAS score decreased by 34.6 (29.1) mm 
from day 0 to the last day. Among the population without 
asthma, mean (SD) troublesomeness with sleep quality 
VAS score decreased by − 32.7 (28.6) mm from baseline 
(Fig. 3).
Troublesomeness of daily activities
The mean (SD) troublesomeness of daily activities at 
work or school VAS score significantly decreased by 35.2 
(25.6) mm in the whole study population (P < 0.0001). 
In the subpopulation of AR with asthma, the mean (SD) 
troublesomeness of daily activities at work or school VAS 
score decreased by 34.3 (27.5) mm. For patients without 
asthma, the mean (SD) decrease from baseline in trouble-
someness of daily activities was 34.7 (26.3) mm (Fig. 4).
Furthermore, in the whole study population, the 
mean (SD) troublesomeness with daily social activities 
VAS score significantly decreased by 33.2 (25.8) mm 
from baseline to the last day (P < 0.0001), whereas the 
Fig. 1 Changes in AR‑VAS Scores With MP‑AzeFlu Treatment. Time course of mean (SEM) VAS scores of AR symptoms from day 0 to the last trial day 
(a) in the total study population and (b) stratified by the presence of comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard 
error of the mean; VAS, visual analog scale
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mean (SD) decrease in the asthma population was 32.6 
(29.2) mm. Among patients with no asthma, the mean 
(SD) change in social activities VAS score was − 32.7 
(26.1)  mm (Fig.  5). Finally, mean (SD) troublesome-
ness with daily outdoor activities VAS scores signifi-
cantly decreased by 40.0 (27.2) mm, 40.2 (30.9), and 39.2 
(28.0)  mm in the general study population (P < 0.0001), 
asthma subpopulation, and no asthma subpopulation, 
respectively (Fig. 6).
Safety
Among the safety analysis population, 20 nonserious 
adverse drug reactions were reported in 14 patients 
(1.3%). The most frequent adverse events included 
epistaxis (0.4%), dysgeusia (0.3%), headache (0.2%), 
and dyspnea (0.2%). Among 267 patients with comor-
bid asthma, 5 nonserious adverse drug reactions were 
reported in 3 patients (1.1%), which was similar to the 
total population. No serious adverse drug reactions 
occurred.
Discussion
This was the first multicenter, prospective, noninterven-
tional, real-life study to evaluate the effect of AR treat-
ment with MP-AzeFlu on asthma symptom severity and 
reliever medication use. A total of 24% of patients with 
AR in this study reported comorbid asthma, which is 
comparable with literature rates of 15% to 38% [1]. We 
showed that patients with moderate-to-severe AR and 
comorbid asthma treated with MP-AzeFlu had similarly 
improved AR symptom severity compared with patients 
with AR alone. Patients with and without comorbid 
asthma also experienced improved quality of life with 
MP-AzeFlu treatment. For patients with asthma, asthma 
symptom severity and asthma reliever medication use 
decreased from baseline.
In general, improvements in AR-VAS scores and 
quality-of-life measures were comparable for patients 
with and without asthma. This is particularly notable 
given that the subpopulation with comorbid asthma had 
numerically higher rates of more severe AR symptoms. 
Although significance testing was not performed across 
populations, the AR with asthma group had a higher rate 
of both perennial and seasonal AR and allergic sensitiza-
tion to more than 5 allergens. Baseline AR-VAS scores, 
however, were only modestly higher in the group with 
asthma. These data suggest MP-AzeFlu treatment may 
have similar effectiveness in populations with and with-
out asthma and with varying levels of AR severity.
VAS scores were used to assess AR symptom severity, 
asthma symptom severity, and quality-of-life measures in 
this study. Advantages of VAS measurements include a 
high degree of resolution, with repeat measures offering 
the opportunity to identify even small changes within and 
among individual patients and groups of patients [21]. In 
addition, VAS scores are good tools for measuring con-
tinuous variables, such as AR and asthma symptoms [21]. 
In past studies, VAS scores have been shown to correlate 
well with the severity of AR according to ARIA guidelines 
[22, 23]. A cutoff variation of 23 mm for VAS was shown 
Fig. 2 Changes in Asthma‑VAS Scores With MP‑AzeFlu Treatment. Time course of mean (SEM) VAS of asthma symptoms from day 0 to lthe last trial 
day among patients with comorbid AR and asthma. AR, allergic rhinitis; SD, standard deviation; SEM, standard error of the mean; VAS, visual analog 
scale
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to correlate well with the established cutoff of 0.5 for the 
Rhinoconjunctivitis Quality of Life Questionnaire [23]. 
Moreover, a change of 30 mm was always correlated with 
positive changes in quality-of-life parameters [23]. In the 
present study, changes in AR-VAS scores from baseline 
to the last day exceeded this cutoff for all endpoints in the 
safety population and the comorbid asthma population, 
suggesting meaningful changes in symptoms and quality 
of life.
VAS scores are not only useful in clinical practice for 
stratifying patients and monitoring response; they have 
also been used as evaluation parameters in randomized 
controlled trials of AR treatment. In 2 studies of AR eval-
uating treatment with INAH, VAS scores discriminated 
between placebo and treatment groups better than total 
symptom scores [24, 25]. In this study, the mean change 
in AR-VAS from baseline to the last day suggests a shift 
from uncontrolled to controlled AR and severe to mild 
AR.
Although VAS scores are less commonly used for 
evaluation of asthma symptoms, they have nonethe-
less been shown to be valid measures for predicting 
asthma control and lung function [26–28]. When VAS 
was evaluated in the morning and evening in adoles-
cent patients with asthma, average VAS scores were 
significantly correlated with both asthma control 
(r = 0.65, P < 0.001) and  FEV1 (r = − 0.38, P = 0.029) 
[26]. In a study of Japanese patients, Global Initiative 
for Asthma–defined control levels were discriminated 
by VAS score cutoff points of 1.50  cm (controlled), 
4.79 cm (partly controlled), and 7.19 cm (uncontrolled) 
Fig. 3 Changes in Troublesomeness of Sleep Quality VAS Scores With 
MP‑AzeFlu Treatment. Time course of mean (SEM) VAS of change of 
troublesomeness of sleep quality from day 0 to the last trial day (a) 
in the total study population and (b) in subpopulations according to 
the presence of comorbid asthma. AR, allergic rhinitis; SD, standard 
deviation; SEM, standard error of the mean; VAS, visual analog scale
Fig. 4 Changes in Troublesomeness of Daily Work and School 
Activities VAS Scores with MP‑AzeFlu Treatment. Time course of 
mean (SEM) VAS of change of troublesomeness of daily work and 
school activities from day 0 to the last trial day (a) in the total study 
population and (b) in subpopulations according to the presence of 
comorbid asthma. AR, allergic rhinitis; SD, standard deviation; SEM, 
standard error of the mean; VAS, visual analog scale
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[28]. According to these cutoffs, the asthma severity 
VAS scores were suggestive of uncontrolled asthma at 
baseline, which is further supported by the use of more 
than 5 puffs of reliever medication on average in the 
week before treatment with MP-AzeFlu. With MP-Aze-
Flu treatment, asthma control improved by the last day 
to partly controlled in the majority of patients (median 
20.0 mm) and to controlled in at least 25% of patients 
(low quartile 5.0 mm). These data are further supported 
by the reduced use of asthma reliever medication at 
study conclusion. Several studies have shown that the 
use of INCS can improve asthma symptoms in patients 
with comorbid AR through the treatment of upper air-
way inflammation, which indirectly decreases bron-
chial hyperreactivity [29, 30]. Therefore, improvement 
in asthma symptoms with MP-AzeFlu treatment could 
be attributed to the improved control of AR symptoms, 
decreased airway inflammation, or, most likely, a com-
bination of the two, which is supported by the moderate 
correlation between AR symptom severity improve-
ment and asthma symptom severity improvement.
The “one airway, one disease” hypothesis suggests joint 
management of AR and asthma leads to better control of 
both diseases [31, 32]. Evidence for the “one airway, one 
disease” hypothesis includes epidemiologic data that sug-
gest the high frequency of comorbid asthma and AR, her-
itability of allergic diseases (e.g., AR, asthma, and atopic 
dermatitis), and the overlapping roles of inflammatory 
mediators in AR and asthma, which are supported by 
the clinical effectiveness of corticosteroids and antihis-
tamines for both conditions. In this study, the moderate 
Fig. 5 Changes in Troublesomeness of Sleep Quality VAS Scores With 
MP‑AzeFlu Treatment. Time course of mean (SEM) VAS of change of 
troublesomeness of sleep quality from day 0 to the last trial day (a) 
in the total study population and (b) in subpopulations according to 
the presence of comorbid asthma. AR, allergic rhinitis; SD, standard 
deviation; SEM, standard error of the mean; VAS, visual analog scale
Fig. 6 Changes in Troublesomeness of Daily Outdoor Activities VAS 
Scores With MP‑AzeFlu Treatment. Time course of mean (SEM) VAS of 
change of daily outdoor activities from day 0 to the last trial day (a) 
in the total study population and (b) in subpopulations according to 
the presence of comorbid asthma. AR, allergic rhinitis; SD, standard 
deviation; SEM, standard error of the mean; VAS, visual analog scale
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correlation between change of general AR-VAS and 
asthma-VAS scores lends additional credence to the “one 
airway, one disease” hypothesis.
Study limitations included the observational design 
and lack of a control group for comparative purposes. 
This limits comparison with previous studies, dur-
ing which data were collected under different circum-
stances. Furthermore, we have limited data surrounding 
clinically relevant features of asthma, including the 
method by which asthma was diagnosed and current 
asthma medications. However, because of the multi-
national, noninterventional study design, information 
about a variety of patients’ allergy characteristics could 
be obtained, and comparison through a preintervention 
and postintervention design was recorded. Although 
the 2-week study period was sufficient for document-
ing a substantial improvement in AR and asthma symp-
tom severity, monitoring of AR symptom control over 
a longer period of time would better inform long-term 
outcomes with MP-AzeFlu treatment.
Conclusion
MP-AzeFlu use was associated with improved AR symp-
toms, asthma symptoms, and quality-of-life measures in 
patients with concomitant asthma. Change in overall AR 
symptoms and change in asthma symptoms were corre-
lated. The results support the “one airway, one disease” 
therapy approach for asthma and AR management.
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